|Articles|April 15, 2003

BioPharm International

  • BioPharm International-04-01-2003
  • Volume 16
  • Issue 4

Getting Ready for Risk-Based GMPs

by Patrick Clinton, BioPharm International As FDA moves toward a new vision of GMP regulations, BioPharm International asked industry experts some key quextions: What form will risk-based GMPs take? What are the benefits and costs for biotech? Will the change really encourage innovation? And, most important, can FDA leaders get field inspectors to buy into the new approach?
To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

almost 23 years ago

Virus Inactivation in the 1990s and into the 21st Century

almost 23 years ago

Using Peptide Maps as Identity and Purity Tests for Lot Release Testing of Recombinant Therapeutic Proteins

almost 23 years ago

GMP Issues: Breaking Ground

almost 23 years ago

Guest Editorial: Benchmarking Biotech

almost 23 years ago

Optimized Nutrient Additives for Fed-Batch Cultures

almost 23 years ago

Commercial Production of Transgenic Crops Genetically Engineered to Produce Pharmaceuticals

almost 23 years ago

Inside Washington: GMP Progress Report

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!